249 related articles for article (PubMed ID: 28507282)
21. AKT inhibition overcomes rapamycin resistance by enhancing the repressive function of PRAS40 on mTORC1/4E-BP1 axis.
Mi W; Ye Q; Liu S; She QB
Oncotarget; 2015 Jun; 6(16):13962-77. PubMed ID: 25961827
[TBL] [Abstract][Full Text] [Related]
22. RRM1, RRM2 and ERCC2 Gene Polymorphisms in Coronary Artery Disease.
Altinkilic EM; Isbir S; Gormus U; Yilmaz SG; Dalan AB; Duman S; Isbir T
In Vivo; 2016 09-10; 30(5):611-5. PubMed ID: 27566080
[TBL] [Abstract][Full Text] [Related]
23. Cell-cycle-dependent phosphorylation of RRM1 ensures efficient DNA replication and regulates cancer vulnerability to ATR inhibition.
Shu Z; Li Z; Huang H; Chen Y; Fan J; Yu L; Wu Z; Tian L; Qi Q; Peng S; Wei C; Xie Z; Li X; Feng Q; Sheng H; Li G; Wei D; Shan C; Chen G
Oncogene; 2020 Aug; 39(35):5721-5733. PubMed ID: 32712628
[TBL] [Abstract][Full Text] [Related]
24. mTORC2 regulates ribonucleotide reductase to promote DNA replication and gemcitabine resistance in non-small cell lung cancer.
Tian L; Chen C; Guo Y; Zhang F; Mi J; Feng Q; Lin S; Xi N; Tian J; Yu L; Chen Y; Cao M; Lai C; Fan J; Zhang Y; Chen G
Neoplasia; 2021 Jul; 23(7):643-652. PubMed ID: 34126361
[TBL] [Abstract][Full Text] [Related]
25. Physical interaction between human ribonucleotide reductase large subunit and thioredoxin increases colorectal cancer malignancy.
Lou M; Liu Q; Ren G; Zeng J; Xiang X; Ding Y; Lin Q; Zhong T; Liu X; Zhu L; Qi H; Shen J; Li H; Shao J
J Biol Chem; 2017 Jun; 292(22):9136-9149. PubMed ID: 28411237
[TBL] [Abstract][Full Text] [Related]
26. p53 Nongenotoxic Activation and mTORC1 Inhibition Lead to Effective Combination for Neuroblastoma Therapy.
Moreno-Smith M; Lakoma A; Chen Z; Tao L; Scorsone KA; Schild L; Aviles-Padilla K; Nikzad R; Zhang Y; Chakraborty R; Molenaar JJ; Vasudevan SA; Sheehan V; Kim ES; Paust S; Shohet JM; Barbieri E
Clin Cancer Res; 2017 Nov; 23(21):6629-6639. PubMed ID: 28821555
[No Abstract] [Full Text] [Related]
27. Reciprocal regulation of autophagy and dNTP pools in human cancer cells.
Chen W; Zhang L; Zhang K; Zhou B; Kuo ML; Hu S; Chen L; Tang M; Chen YR; Yang L; Ann DK; Yen Y
Autophagy; 2014 Jul; 10(7):1272-84. PubMed ID: 24905824
[TBL] [Abstract][Full Text] [Related]
28. Rapamycin causes poorly reversible inhibition of mTOR and induces p53-independent apoptosis in human rhabdomyosarcoma cells.
Hosoi H; Dilling MB; Shikata T; Liu LN; Shu L; Ashmun RA; Germain GS; Abraham RT; Houghton PJ
Cancer Res; 1999 Feb; 59(4):886-94. PubMed ID: 10029080
[TBL] [Abstract][Full Text] [Related]
29. Inhibition of mTOR complex 1/p70 S6 kinase signaling elevates PD-L1 levels in human cancer cells through enhancing protein stabilization accompanied with enhanced β-TrCP degradation.
Deng L; Qian G; Zhang S; Zheng H; Fan S; Lesinski GB; Owonikoko TK; Ramalingam SS; Sun SY
Oncogene; 2019 Aug; 38(35):6270-6282. PubMed ID: 31316145
[TBL] [Abstract][Full Text] [Related]
30. ATR-CHK1-E2F3 signaling transactivates human ribonucleotide reductase small subunit M2 for DNA repair induced by the chemical carcinogen MNNG.
Gong C; Liu H; Song R; Zhong T; Lou M; Wang T; Qi H; Shen J; Zhu L; Shao J
Biochim Biophys Acta; 2016 Apr; 1859(4):612-26. PubMed ID: 26921499
[TBL] [Abstract][Full Text] [Related]
31. Stable suppression of the R2 subunit of ribonucleotide reductase by R2-targeted short interference RNA sensitizes p53(-/-) HCT-116 colon cancer cells to DNA-damaging agents and ribonucleotide reductase inhibitors.
Lin ZP; Belcourt MF; Cory JG; Sartorelli AC
J Biol Chem; 2004 Jun; 279(26):27030-8. PubMed ID: 15096505
[TBL] [Abstract][Full Text] [Related]
32. Functional Genomic Screen in Mesothelioma Reveals that Loss of Function of BRCA1-Associated Protein 1 Induces Chemoresistance to Ribonucleotide Reductase Inhibition.
Okonska A; Bühler S; Rao V; Ronner M; Blijlevens M; van der Meulen-Muileman IH; de Menezes RX; Wipplinger M; Oehl K; Smit EF; Weder W; Stahel RA; Penengo L; van Beusechem VW; Felley-Bosco E
Mol Cancer Ther; 2020 Feb; 19(2):552-563. PubMed ID: 31619462
[TBL] [Abstract][Full Text] [Related]
33. Silencing of ribonucleotide reductase subunit M1 potentiates the antitumor activity of gemcitabine in resistant cancer cells.
Wonganan P; Chung WG; Zhu S; Kiguchi K; Digiovanni J; Cui Z
Cancer Biol Ther; 2012 Aug; 13(10):908-14. PubMed ID: 22785206
[TBL] [Abstract][Full Text] [Related]
34. Inhibiting WEE1 Selectively Kills Histone H3K36me3-Deficient Cancers by dNTP Starvation.
Pfister SX; Markkanen E; Jiang Y; Sarkar S; Woodcock M; Orlando G; Mavrommati I; Pai CC; Zalmas LP; Drobnitzky N; Dianov GL; Verrill C; Macaulay VM; Ying S; La Thangue NB; D'Angiolella V; Ryan AJ; Humphrey TC
Cancer Cell; 2015 Nov; 28(5):557-568. PubMed ID: 26602815
[TBL] [Abstract][Full Text] [Related]
35. Analysis of ribonucleotide reductase M2 mRNA levels in patient samples after GTI-2040 antisense drug treatment.
Juhasz A; Vassilakos A; Chew HK; Gandara D; Yen Y
Oncol Rep; 2006 May; 15(5):1299-304. PubMed ID: 16596201
[TBL] [Abstract][Full Text] [Related]
36. Cancer Fighting SiRNA-RRM2 Loaded Nanorobots.
Sharma A; Kumar P; Ambasta RK
Pharm Nanotechnol; 2020; 8(2):79-90. PubMed ID: 32003677
[TBL] [Abstract][Full Text] [Related]
37. The identification of novel 5'-amino gemcitabine analogs as potent RRM1 inhibitors.
Labroli MA; Dwyer MP; Shen R; Popovici-Muller J; Pu Q; Wyss D; McCoy M; Barrett D; Davis N; Seghezzi W; Shanahan F; Taricani L; Beaumont M; Malinao MC; Parry D; Guzi TJ
Bioorg Med Chem; 2014 Apr; 22(7):2303-10. PubMed ID: 24588962
[TBL] [Abstract][Full Text] [Related]
38. RRM1 and RRM2 pharmacogenetics: association with phenotypes in HapMap cell lines and acute myeloid leukemia patients.
Cao X; Mitra AK; Pounds S; Crews KR; Gandhi V; Plunkett W; Dolan ME; Hartford C; Raimondi S; Campana D; Downing J; Rubnitz JE; Ribeiro RC; Lamba JK
Pharmacogenomics; 2013 Sep; 14(12):1449-66. PubMed ID: 24024897
[TBL] [Abstract][Full Text] [Related]
39. mTORC1 Couples Nucleotide Synthesis to Nucleotide Demand Resulting in a Targetable Metabolic Vulnerability.
Valvezan AJ; Turner M; Belaid A; Lam HC; Miller SK; McNamara MC; Baglini C; Housden BE; Perrimon N; Kwiatkowski DJ; Asara JM; Henske EP; Manning BD
Cancer Cell; 2017 Nov; 32(5):624-638.e5. PubMed ID: 29056426
[TBL] [Abstract][Full Text] [Related]
40. Bone marrow ribonucleotide reductase mRNA levels and methylation status as prognostic factors in patients with myelodysplastic syndrome treated with 5-Azacytidine.
Kontandreopoulou CN; Diamantopoulos PT; Giannopoulos A; Symeonidis A; Kotsianidis I; Pappa V; Galanopoulos A; Panayiotidis P; Dimou M; Solomou E; Loupis T; Zoi K; Giannakopoulou N; Dryllis G; Hatzidavid S; Viniou NA;
Leuk Lymphoma; 2022 Mar; 63(3):729-737. PubMed ID: 34738857
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
